Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 11/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.94 |
| ▸ | RAD52 | P43351 | 2/20 | 0.94 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.61 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372738 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL15965174 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8381473 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8386909 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL1172093 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8383501 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL668301 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL1171874 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8386779 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL37593 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005094806-A1 | USE OF QUATERNARY AMMONIUM COMPOUNDS AS SPECIFIC BLOCKERS OF TRANSPORT THROUGH AQUAPORIN, COMPOSITIONS COMPRISING THE COMPOUNDS AND METHOD OF SELECTING THE COMPOUNDS | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2005-10-13 | — | — | WO | claimed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| US-11914295-B2 | Thermosetting iodine- and silicon-containing material, composition containing the material for forming resist underlayer film for EUV lithography, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20230333472-A1 | THERMOSETTING IODINE- AND SILICON-CONTAINING MATERIAL, COMPOSITION CONTAINING THE MATERIAL FOR FORMING RESIST UNDERLAYER FILM FOR EUV LITHOGRAPHY, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230244149-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-9315670-B2 | Composition for forming resist underlayer film and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20140235796-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER FILM AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| WO-2005094806-A1 | USE OF QUATERNARY AMMONIUM COMPOUNDS AS SPECIFIC BLOCKERS OF TRANSPORT THROUGH AQUAPORIN, COMPOSITIONS COMPRISING THE COMPOUNDS AND METHOD OF SELECTING THE COMPOUNDS | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2005-10-13 | — | — | WO | disclosed |
| US-5955584-A | NON-PROTEIN ANTIGEN COMPOSED OF STEROID COMPONENT WITH 3 BETA HYDROXY OR 3 KETO GROUP AND QUATERNARY AMMONIUM SALT; FOR THERAPY AND IMMUNOASSAY DIAGNOSIS | CHARTER VENTURES (US) | 1999-09-21 | — | — | US | disclosed |
| US-5811248-A | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof | CHARTER VENTURES (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230333472-A1 | THERMOSETTING IODINE- AND SILICON-CONTAINING MATERIAL, COMPOSITION CONTAINING THE MATERIAL FOR FORMING RESIST UNDERLAYER FILM FOR EUV LITHOGRAPHY, AND PATTERNING PROCESS | RPS4X, SIK3, MLX | DNM1 4060/4885HTT 2857/4885KMT2A 1118/4885 |
| US-11914295-B2 | Thermosetting iodine- and silicon-containing material, composition containing the material for forming resist underlayer film for EUV lithography, and patterning process | RPS4X, SIK3, MLX | DNM1 4060/4885HTT 2857/4885KMT2A 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.